Physician profile
Brian D Jackson
NPI 1467497461
$2,492.61
in general payments reported to CMS, 2019-2025
15 companies · $985 in 2025
The $985 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.97 · 2022: $279 · 2023: $477 · 2024: $665 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.46 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $891.32 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $870.96 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $167.92 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $106.38 | 2025 | Neffy |
| Abbvie INC. | $100.00 | 2025 | |
| Genzyme Corporation | $95.24 | 2024 | |
| Abiomed | $63.59 | 2025 | |
| Tela Bio, INC. | $48.05 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Regeneron Healthcare Solutions, INC. | $38.54 | 2025 | Dupixent |
| Verona Pharma, INC. | $23.28 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $21.30 | 2025 | Xhance |
| Boston Scientific Corporation | $20.38 | 2021 | |
| Merck Sharp & Dohme LLC | $17.24 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.77 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.